Table 3.
Factors related to functioning during long-term follow-up.
| Good (n = 20) | Partial(n = 16) | Limited (n = 19) | p | |
|---|---|---|---|---|
| Age at recruitment, years | 22.4 ± 5.0 | 19.9 ± 4.0 | 20.1 ± 3.1 | 0.146 |
| Length of follow-up, years | 10.6 ± 1.5 | 9.9 ± 2.0 | 9.1 ± 2.3 | 0.072 |
| Gender (Male) | 6 (30.0) | 4 (25.0) | 12 (63.2) | 0.037 |
| UHR+ | 8 (40.0) | 3 (18.8) | 6 (31.6) | 0.390 |
| Diagnosis | ||||
| Non-Affective psychosis Affective psychosis Other† |
16 (80.0) 2 (10.0) 2 (10.0) |
12 (75.0)2 (12.5)2 (12.5) | 18 (94.7) 1 (5.3) 0 (0) |
0.526 |
| Never hospitalized | 13 (65.0) | 9 (56.3) | 6 (31.6) | 0.100 |
| On clozapine | 1 (5) | 1 (6.3) | 6 (31.6) | 0.034 |
| On LAIA | 2 (10.0) | 2 (12.5) | 2 (10.5) | 0.970 |
| CPZE < 200 mg/d | 15 (75.0) | 2 (12.5) | 0 (0) | <0.001 |
| CPZE < 50 mg/d | 8 (40.0) | 2 (12.5) | 0 (0) | 0.003 |
†
Other diagnoses include brief psychotic disorder, schizotypal disorder, and non-psychotic disorder. UHR+, ultra-high risk subjects converting to first episode psychosis after recruitment; CPZE, chlorpromazine equivalent; LAIA, long-acting injectable antipsychotic.